Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -128.4%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $3M | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $-2169977 | $-269089 | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.78 | 4.33 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.19 | 0.47 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.36 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.5% | 18.5% | 100.0% | 100.0% | — | — | — | — | -2784.7% | — | -1024.2% |
| Operating Margin | -1128.1% | -1128.1% | -27916.3% | -6060.2% | — | — | — | — | -6365.3% | — | -1678.5% |
| Net Profit Margin | -401.3% | -401.3% | -26074.4% | -5370.2% | — | — | — | — | -4858.7% | — | -1398.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -128.4% | -128.4% | — | -214.4% | -72.9% | -52.0% | -37.6% | -58.1% | -39.4% | -41.5% | -71.2% |
| ROA | -48.8% | -48.8% | -173.8% | -122.4% | -59.6% | -46.2% | -32.4% | -44.6% | -31.8% | -32.7% | -53.1% |
| ROIC | -189.3% | -189.3% | — | — | -1235.4% | -1619.3% | -834.0% | -724.0% | — | — | — |
| ROCE | -360.2% | -360.2% | — | -240.3% | -94.9% | -62.2% | -45.1% | -68.5% | -51.2% | -52.3% | -84.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | 0.06 | 0.01 | 0.00 | 0.03 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.51 | — | -5.50 | -0.89 | -0.97 | -0.97 | -0.91 | -1.15 | -1.10 | -1.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($2000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.70 | 4.70 | 0.59 | 0.91 | 3.25 | 7.56 | 14.27 | 5.79 | 4.45 | 6.32 | 3.73 |
| Quick Ratio | 3.66 | 3.66 | 0.59 | 0.91 | 3.25 | 7.56 | 14.27 | 5.79 | 4.45 | 6.32 | 3.73 |
| Cash Ratio | 2.63 | 2.63 | 0.50 | 0.41 | 2.44 | 6.75 | 13.44 | 4.91 | 3.93 | 5.85 | 3.17 |
| Asset Turnover | — | 0.09 | 0.01 | 0.05 | — | — | — | — | 0.01 | — | 0.04 |
| Inventory Turnover | 0.44 | 0.44 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 614.20 | 2011.74 | 3237.20 | — | — | — | — | 3659.73 | — | 890.63 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 4.6% | 1.9% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 4.6% | 1.9% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $2M | $22314 | $3545 | $3126 | $2479 | $1009 | $227 | $168 | $106 | $48 |
Persistent equity dilution risk
Based on reported figures, the company trades at a price-to-sales ratio of 1.78, which appears disconnected from its negative operating margins and suggests that investors are pricing the stock as a speculative shell rather than a viable industrial service provider with predictable cash flow generation.
The current valuation multiple reflects a high-risk premium, as the market likely assigns value to the biopharmaceutical pipeline rather than the fire protection segment. Investors should monitor whether this P/S ratio compresses as the market reconciles the company's inability to achieve profitability with its current cost structure.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -5.5% in 2026Q1, which indicates that the firm is currently destroying shareholder value rather than compounding it through its dual-track strategy of industrial fire safety and early-stage biopharmaceutical research and development.
The persistent negative return on capital suggests that the company's investments are not generating sufficient returns to cover the cost of capital. This trend warrants further investigation into whether the recent acquisition of Fitters Sdn. Bhd. can ever achieve the scale necessary to turn these returns positive.
According to recent SEC filings, the company's cash conversion cycle remains highly volatile, with a 2026Q1 figure of 245 days, reflecting significant challenges in managing receivables and inventory within the fragmented Malaysian fire protection market compared to more efficient industrial peers in the broader healthcare sector.
The extended DSO and DIO suggest that the company faces structural difficulties in converting its project-based revenue into actual cash. This inefficiency appears to be a primary driver of the company's liquidity strain, as capital remains tied up in long-duration contracts and slow-moving inventory.
Based on the most recent quarterly data, the company maintains a current ratio of 7.06, yet this metric appears misleading as it is heavily supported by cash reserves that are being rapidly depleted to fund ongoing operating losses rather than sustainable business growth or operational expansion.
While the current ratio suggests a comfortable liquidity position, the underlying cash burn rate indicates that this buffer is temporary. Investors should monitor the cash runway closely, as the company's reliance on external financing remains a critical risk to its long-term solvency.
Financial analysts frequently misapply the price-to-sales ratio to this business model, as it ignores the massive disparity between the low-margin industrial fire safety revenue and the high-burn, pre-revenue biopharmaceutical segment, effectively masking the company's true lack of earning power and structural profitability challenges.
A more appropriate metric would be a cash-burn-adjusted valuation or a segment-specific EV/EBITDA, which would better highlight the company's inability to generate positive cash flow. Relying on P/S ratios in this context obscures the fundamental risk that the company may require further dilutive equity raises to survive.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BGMS stock.
Bio Green Med Solution, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Bio Green Med Solution, Inc.'s return on equity (ROE) is -128.4%. The historical average is -101.2%.
Based on historical data, Bio Green Med Solution, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bio Green Med Solution, Inc.'s current dividend yield is 4.57%.
Bio Green Med Solution, Inc. has 18.5% gross margin and -1128.1% operating margin.